Compare VanEck Australian Floating Rate ETF (FLOT) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs Hinge Health Inc. Class A Common Stock — how do they compare? VanEck Australian Floating Rate ETF trades at $50.93 (market cap $11.37B), while Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B). The key difference: VanEck Australian Floating Rate ETF is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Australian Floating Rate ETF for 23 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| FLOT | HNGE | |
|---|---|---|
Market Cap | $11.37B | $8.47B |
Volume | 2,911,131 | 1,624,526 |
Sector | Fixed Income | Health |
52-Week High | $51.07 | $105.14 |
52-Week Low | $50.72 | $31.17 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | — | $8.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.95 with minimal daily movement (+0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The ETF benefits from floating rate exposure amid Fed tightening, with recent dividends of $0.17-$0.18 paid through October 2026. News highlights concentration risk with 47% bank exposure but positions FLOT as a cash substitute in rising rate environments.
Outlook remains tied to Fed policy, with floating rates offering yield advantage if hikes persist. Key risks include bank sector concentration and rate reversal. Analyst sentiment is cautious due to technical weakness but acknowledges strategic utility for barbell portfolios alongside duration assets.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
